Pharmaceutical Treatment of Asthma Symptoms in Elite Athletes - Doping or Therapy by Jimmi Elers & Vibeke Backer
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
27 
Pharmaceutical Treatment of Asthma 
Symptoms in Elite Athletes – Doping or Therapy 
Jimmi Elers and Vibeke Backer 
Copenhagen University, 
Denmark 
1. Introduction 
According to the World Health Organization (WHO), 300 million people suffer from asthma, a 
disease which is increasing in western societies, and furthermore asthma is the most common 
chronic disease among children, adolescents and young adults. A steady increase in the 
prevalence of asthma, has been seen in most countries in recent decades (Thomsen et al 2011) 
and the higher frequency of asthma in young people may partly explain the high frequency 
found in elite athletes – although both frequency of asthma symptoms and use of anti-
asthmatic medication are different than expected. Moreover, the frequency of airway 
hyperresponsiveness (AHR) in elite athletes is higher than expected as well as the frequency of 
asthma-like symptoms (cough, wheeze, shortness of breath and chest tightness) which might 
be caused by exhaustive ventilation, but the pathogenesis is still unknown. 
The frequency of asthma among the general population is around 7-10%; whereas the 
frequency of asthma among elite athletes is found to be higher, especially among endurance 
athletes (Pedersen et al 2008b). It seems as asthma is something they gain, as only one third 
of Olympic athletes had childhood asthma. Although asthma among the general public is a 
permanent phenomenon, it seems to be different in elite athletes, as asthma apparently 
disappeared after retiring from the sport (Fitch et al 2008).   
2. Asthma among athletes 
Asthma is a chronic respiratory condition classically characterised by airway inflammation 
and airway hyperresponsiveness (AHR) to multiple stimuli (Anderson et al 2009). AHR is 
defined as a pathological bronchoconstrictive response to a given stimulus . AHR to a direct 
stimulus (e.g. methacholine) acts through airway smooth muscles and the response is 
thought to be independent of airway inflammation. Whereas response to an indirect 
stimulus (e.g. exercise, hyperventilation, mannitol) acts through a release of inflammatory 
mediators, such as histamine, prostaglandins, and leukotrienes, which causes contraction of 
the airway smooth muscle cells. Airway inflammation in asthma is characterised by 
inflammatory cells, such as eosinophils, mast cells, and macrophages. The inflammation 
causes remodelling of the basal membrane, enlargement of the mass of smooth muscles, and 
disturbance of the surface area. Permanent use of controller therapy with inhaled steroids 
(ICS) is needed in asthma, as well as relief therapy with short-acting beta2-agonists (SABA), 
long-acting beta2-agonists (LABA) or others. 
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Elite athletes, with or without asthma, have asthma-like symptoms during their training 
season, especially cough, phlegm and shortness of breath is a dominant complain among 
athletes (Lund et al 2009). Furthermore, athletes are more often found with AHR to direct 
stimuli and less to direct stimuli than found in normal subjects thus suggesting a respiratory 
illness. Variation in action of the different provocative agents is related to the fact that 
response to an indirect challenge would reflect an ongoing inflammation better than would 
direct tests, and perhaps thus reflect the presence of classical asthma, whereas AHR to direct 
agents indicates airway smooth muscle dysfunction and, in some cases, asthma (Pedersen et 
al 2008a, Sue-Chu et al 2010).  
The definition of asthma includes respiratory symptoms, variable airway obstruction and 
airway hyperresponsiveness to multiple agents. The respiratory symptoms in patients with 
common asthma and the elite athletes with or without asthma are similar, which leave a 
diagnostic problem in these cases where symptoms are the single diagnostic parameter 
available. Whereas, the differences between common asthma and asthma among elite 
athletes are predominantly related to the airway responsiveness to inhaled agents, the day-
to-day variability of lung function as well as the content of the inflammatory cells which 
predominantly are neutrophilic cells and not eosinophilic. 
3. Exercise-induced asthma and bronchoconstriction in elite athletes  
Exercise-induced bronchoconstriction (EIB) is an acute, transient narrowing of the airway 
that occurs during and particularly after exercise. In most scientific papers, exercise-induced 
asthma (EIA) are defined as respiratory symptoms and a significant reduction in FEV1 after 
exercise, i.e. ∆ FEV1 ≥ 10%, whereas EIB is a significant reduction in FEV1 (≥10%) when 
tested, independent of symptoms or not. In population samples, the prevalence of EIB (16%) 
is the same as the findings of AHR to histamine (16%), although only 6% had responsiveness 
to both test (Backer et al 1992). EIB is believed to be more specific to asthma, but less 
sensitive, as the number of false negative results is a problem when research and clinical 
situations settings are evaluated (Anderson & Kippelen 2005). The frequency of AHR is 
frequently found above 40%, which is higher than the frequency of asthma.  Elite athletes 
claim that exercise is the most prominent trigger of asthma symptoms, as they very seldom 
complain of respiratory symptoms at rest or during the night.  
The pathogenesis of asthma-like symptoms in elite athletes is multifactorial, and is not 
completely understood. However, deep, exhaustive ventilation during exercise brings 
atmospheric air which is cold and dry and this manoeuvre overcomes the ability of the 
upper airways to warm up and humidify the air reaching the smaller airways(Anderson 
& Kippelen 2005). This brings about airway narrowing due to osmotic and thermal 
evaporative water loss, and some vascular involvement. These airway differences, 
together with some degree of inflammation, lead to a respiratory condition described as 
EIB or sports asthma. This abnormal response is most often found in endurance sports, 
such as cross-country skiing , swimming, rowing, cycling, fast-track skating and long 
distance running.   
The symptoms of exercise-induced bronchoconstriction range from mild impairment of 
performance with minor reduction in lung function after exercise to severe bronchospasm 
with large reduction in FEV1. In athletes, however, the most common symptoms include 
cough, wheezing, chest tightness, dyspnoea, and fatigue. These symptoms are frequently 
found in healthy subjects, subjects with asthma, subjects who are not in good condition and 
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sometimes in subjects suffering from an extrathoracal disorder such as vocal cord 
dysfunction (VCD).  
In conclusion, the most frequent complaint among healthy and diseased athletes is 
respiratory symptoms during exercise.  Furthermore, healthy elite athletes often have AHR  
with a pattern which differ from the general asthma patient. Lastly, the types of cells 
involved in the inflammation are different from those in normal asthmatics. 
4. Diseases mimicking exercise-induced asthma 
Not all that wheezes is asthma. When the diagnosis of asthma is based on respiratory 
symptoms alone, misdiagnosis may occur. Patients may present with respiratory distress, 
such as wheezy, when experiencing a low level of fitness, a psychological condition, 
inhalation of airborne irritants, rhinosinusitis, or gastroesophageal reflux disease. Moreover, 
exercise-induced symptoms can occur as periodic occurance of laryngeal obstruction 
(POLO) or exercise induced laryngeal obstruction (EILO) and present with asthma like 
symptoms. These diseases include conditions such as vocal cord dysfunction (VCD), 
exercise-induced paradoxical arytenoid motion (EPAM), exercise-induced laryngomalacia 
(EIL), exercise-induced laryngochalasia, angioedema, vocal cord tumours, and vocal cord 
paralysis. There seems to be a substantial overlap between EILO and EIA, at least in elite 
athletes. It could be of minor importance, but it could also have a major influence on the 
diagnostic procedure in the daily care settings of those with asthma-like symptoms. When 
POLO/EILO is misdiagnosed as asthma, patient are erroneously treated with anti-asthma 
therapy, even high doses because of  “resistant disease”.    
These diseases are easily recognized by performing a Flow/Volume curve where a classical 
cutoff of the inspiratory loop is apparent. On the other hand, a specific diagnose of the 
actual pathology need laryngeal examination during exercise. The definitive diagnosis of 
laryngeal obstruction might require laryngoscopy during strenuous exercise. Heimdal et al 
(Heimdal et al 2006) recently published a paper describing a model for use when 
performing the continuous laryngoscopy exercise test (CLE). Patients with asthma should 
start asthma medication, and for those with satisfactory adherence who do not achieve well-
controlled disease, other reasons for persistent respiratory symptoms should be explored. In 
such cases CLE should be performed.  
5. Treatment 
Treatment of elite athletes with asthma can be divided into non-pharmacological and 
pharmacological treatment. During the last decades the International Olympic Committee 
(IOC) increased their focus on the increasing use of anti-asthmatic medication by Olympic 
and other elite athletes. At the 1996 Olympic Games in Atlanta 3.7% of the athletes used 
beta2-agonists, 5.6% at the 1998 Winter Games in Nagano, and 5.7% at the Sydney Games 
2000. The IOC and the World Anti Doping Agency (WADA) have had many changes in the 
anti-doping regulations on beta2-agonists through the years, partly due to concerns 
regarding ergogenic effects and partly because of health risk concerns. Due to the increased 
use of beta2-agonists as mentioned above the IOC introduced a criterion of demonstration of 
asthma by an objective measure of reversibility or bronchial airway hyperresponsiveness in 
order approved use of beta2-agonist. This resulted in a 27% reduction in the use of beta2-
agonists in the 2004 Games in Athen.  
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5.1 Pharmacological treatment 
Treatment of asthma and exercise-induced bronchoconstriction (EIB) in elite athletes should 
follow international asthma treatment guidelines like the Global Initiative for Asthma 
(GINA), see Figure 1 (Bateman et al 2008). The main purpose of pharmacotherapy is control 
of asthma symptoms, reducing airway inflammation and airway hyperresponsiveness, 
achieving normal lung function, and prevent exacerbations 
 
Step1 Step2 Step3 Step4 Step5 
 Asthma 
education  
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control 
 
Short-acting 
beta2-agonist 
as needed 
 Short-acting 
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Theophylline  
  
Fig. 1. Management approach. Adapted from GINA. 
5.2 Beta2-agonists 
Inhaled short acting beta2-agonists (SABA), e.g. salbutamol and terbutaline, are first choice 
therapy for fast relief of EIB. Moreover, SABA is useful in preventing EIB if taken 15 minutes 
before exercise. Frequent and increased use indicates uncontrolled asthma and should result 
in reassessment of treatment strategies. Side effects are tremor, tachycardia, palpitations and 
headache, which increase in frequency and intensity with higher doses. With high systemic 
doses hypopotassemia and muscle convulsions can occur. Systemic use of beta2-agonists by 
elite athletes is entirely prohibited according to the Prohibited List, see Table 1. 
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Inhaled long acting beta2-agonists (LABA), e.g. salmeterol and formoterol, are used in 
management of uncontrolled asthma treated with inhaled corticosteroid alone. LABA is 
used as add-on therapy to inhaled corticosteroids, either as fixed combination or in two 
separate devices. LABA should never be used as monotherapy in asthma due to risk of 
serious adverse events with increased risk of mortality in case of exacerbation. In a review 
from 2005 it was concluded that combined fluticasone and salmeterol was superior to 
fluticasone as monotherapy in preventing EIA. Furthermore, in a randomized, double-
blinded study combined budesonide/formoterol was compared with budesonide alone, 
asthma control was better with reduced symptoms when treated with combination of 
budesonide/formoterol. A new study from 2010 confirms previous findings with more 
efficacy when inhaled budesonide is combined with formoterol among adults and 
adolescents with moderate to severe asthma. These findings indicate that it is not an effect 
related to the specific drug, but a class effect of the combination. 
 
I SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES  
(IN- AND OUT-OF-COMPETITION): 
S0. Non-approved substances 
S1. Anabolic agents 
S2. Peptide hormones, growth factors and related substances 
S3. Beta2-agonists 
S4. Hormone antagonists and modulators  
S5. Diuretics and other masking agents   
M1. Enhancement of oxygen transfer  
M2. Chemical and physical manipulation  
M3. Gene doping 
  
II SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION:  
S0-5 and M1-3 defined above 
S6. Stimulants  
S7. Narcotics 
S8. Cannabinoids 
S9. Glucocorticosterooids 
 
III SUBSTANCES PROHIBITED IN PARTICULAR SPORTS:  
P1. Alcohol  
P2. Beta-Blockers 
Table 1. The 2011 Prohibited List by World Anti-Doping Agency. 
It is well known that regular use of beta2-agonist could lead to development of tolerance to 
bronchodilation (i.e. reduced bronchodilator response during acute asthma) and 
bronchoprotection (i.e. reduced ability to prevent exercise-induced bronchoconstriction). 
Tolerance to bronchodilator develops rapidly, after only few doses, and regardless of 
ongoing treatment with inhaled corticosteroid. Tolerance to bronchoprotection develops 
after few weeks of treatment and regardless of ongoing treatment with inhaled 
corticosteroids. The decreased bronchoprotection might result in increased use of beta2-
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
550 
agonist and higher risk of side effects. Though theoretical concerns that regular beta2-
agonist treatment may lead to tolerance and failure to respond to emergency asthma 
treatment, there is little evidence that this is a clinical problem. However, as elite athletes 
exercise daily and often several times a day, use of beta2-agonists, either before exercise to 
prevent bronchoconstriction or during/after due to bronchoconstriction, would exceed the 
maximal recommend weekly use in the GINA guidelines, indicating that other treatment 
strategies than SABA in case of EIB are needed.  
5.3 Inhaled corticosteroids 
Inhaled corticosteroids (ICS) are the most used and most effective inhaled anti-inflammatory 
drug available. ICS improves asthma symptoms, self-reported quality of life and lung 
function, reduces airway inflammation and airway hyperresponsiveness and furthermore, ICS 
has been found to reduce number and severity of exacerbations and asthma mortality (Jeffery 
et al 1992, Suissa et al 2000). GINA guidelines recommend ICS when asthma is uncontrolled 
with non-pharmacological interventions and rescue therapy alone. Effects are observed after 7-
14 days, while full effects are seen after eight weeks of treatment. 
Our current knowledge about effects of ICS on exercise-induced bronchoconstriction is 
based on adults and children with asthma. Existing studies ranges from three weeks to two 
years duration of treatment, mostly conducted in a parallel design. A study with 40 adult 
asthmatic subjects randomized to 6 weeks treatment with placebo or 800 micrograms 
budesonide twice a day showed a post-exercise fall in FEV1 of 7% in the budesonide group 
and to 22% in the placebo group.  Similar findings are reported in asthmatic children. 
5.4 Leukotriene modifiers 
Leukotriene modifiers have anti-inflammatory and bronchodilatory effects. Leukotriene 
modifiers are administered orally and once daily for montelukast and twice daily for 
zileuton. Montelukast is used as add-on treatment in case of uncontrolled asthma with 
medium dose ICS as monotherapy(Lofdahl et al 1999). Prevention of EIA is another 
indication in elite athletes with asthma. Studies report a reduced post-exercise fall in FEV1 
and a reduced period of bronchoconstriction after exercise when treated with montelukast 
compared to placebo in non-smoking asthmatic subjects. No studies have reported 
development of tolerance during regular use.  
5.5 Cromoglycate 
In a study from 2010 treatment with sodium cromoglycate decreased the FEV1 fall after a 
eucapnic voluntary hyperpnoea (EVH) challenge in elite athletes with EIB (Anderson et al 
2010). This finding support that release of mast cell mediators is an important factor for the 
severity of EIB. However, use of cromones in asthmatic elite athletes is limited. 
6. Non-pharmacological interventions 
Asthmatic athletes with pollen allergy should avoid prolonged outdoor endurance exercise 
in areas with high pollen counts. Exercise in temperatures below minus 15 degrees Celsius 
should be avoided, particularly in areas with air pollution or other airway irritants. 
Few studies have investigated correlation between physical warm-up and degree of EIA 
in asthmatic athletes and a warm-up period has been shown to induce refractoriness to 
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EIA without itself inducing significant bronchoconstriction. The protective effect of 
different types of warm-up has been compared in controlled studies, but no consensus is 
found. Different study protocols and designs make it difficult to compare the existing 
studies, but physical warm-up in some form and extent seems generally to have a 
protective effect on EIA, and physical warm-up should be advised for all athletes with 
asthma. Breathing filters may reduce EIB among those exercising in cold conditions. A 
study from 2000 compared response to exercise in cold air (decrease in FEV1) in nine 
patients with EIA when given no treatment, given premedication with a beta2-agonist, 
wearing a heat-and-moisture-exchanging facemask, and given both premedication and 
facemask. The mean maximal change in FEV1 was 27% with no treatment, 12% with 
facemask, 7% with premedication, and no change with the combination of premedication 
and facemask. Another study from 2006 examined effects of a heat exchanger mask, 
placebo mask, and premedication with a beta2-agonist. Five patients with EIA performed 
a treadmill exercise test while breathing cold air. It was concluded that a heat exchanger 
mask prevented cold exercise-induced fall in lung function as effectively as treatment 
with beta2 agonist before exercise in cold air.  
During the last decade some research has focused on nutritional factors, especially omega-3-
polyunsaturated fatty acids’ influence on airway inflammation and exercise-induced 
bronchoconstriction. A review from 2005 concluded that omega-3-polyunsaturated fatty 
acid supplementation reduces the degree of exercise-induced bronchoconstriction compared 
with placebo in patients with EIA. The review was based on a small number of studies with 
limited range of clinically important outcomes. Further controlled and well-designed 
research is needed to establish any evidence-based recommendations.  
7. Treatment or doping 
As mentioned above the IOC and WADA have increased their attention on the status of 
beta2-agonists on the “The 2010 Prohibited List” (www.wada-ama.org). Until the end of 
2009 granting of a Therapeutic Use Exemption (TUE) was necessary for use of inhaled 
salbutamol, terbutaline, salmeterol and formoterol. From 2010 use of inhaled salbutamol 
and salmeterol in therapeutic doses are allowed. From 2010 use of inhaled terbutaline and 
formoterol is still prohibited and requires a TUE and a reasonable explanation of why these 
drugs are prescribed when other equal drugs are permitted. Use of inhaled corticosteroids 
in therapeutic doses is permitted, except when used in a fixed combination with formoterol, 
which requires a TUE. Use of oral or topical antihistamines or leukotriene modifiers is 
permitted. Use of systemic corticosteroids is prohibited during competition. Systemic intake 
of beta2-agonist and clenbuterol is strictly prohibited in elite athletes. The criteria for 
granting a TUE, the “Prohibited List”, and guidelines are available on WADA’s website 
(www.wada-ama.org). As the anti-doping legislation and the prohibited list are continually 
updated, it is important to be familiar with the current regulations before prescribing 
asthma medication to an elite athlete with asthma. The 2011 Prohibited List is shown in 
Table 2. For details visit WADA´s website. 
In the academic societies of sports and pulmonary medicine it is discussed whether or not 
beta2-agonists have any ergogenic, i.e. performance enhancing effects, and if it should be 
considered doping or not. According to the World Anti-Doping Agency (WADA) minimum 
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two of three criteria must be met in order to consider a substance or method for inclusion on 
the Prohibited List: 
1. The substance or method can be performance enhancing 
2. The use of the substance or the method can endanger the athlete´s health 
3. The use of the substance or method is against the spirit of sport 
As it appears a substance or method can be listed without being performance enhancing. 
Due to health issues the IOC considers inhaled use of beta2-agonist without need 
unacceptable. Beta2-agonists have received much attention the last decades because of side 
effects, and few studies have reported and the US Food and Drug Administration have 
issued some concerns about beta2-agonists and side effects/serious adverse events. 
Regarding health issues in elite athletes using beta2-agonists the IOC is concerned about 
athletes using beta2-agonists without need and in supratherapeutic doses. Studies in 
asthmatic children have shown both significant raised and normal blood levels of 
myocardial stress markers after inhalation of beta2-agonists in ten times prophylactic doses. 
Studies with unrestrained rats have documented dose-response myocyte apoptosis after 
administration of the beta2-agonists formoterol and clenbuterol. Significant changes in 
human cardiac electrophysiological properties is seen after administration of salbutamol 5 
mg as a single dose.  
Several studies have investigated the ergogenic effects of inhaled and oral beta2-agonists 
conducted with healthy well-trained men, most studies in therapeutic doses. The 
extensive research on therapeutic doses of inhaled beta2-agonsits clearly rules out any 
ergogenic effects. Only few studies have shown ergogenic effects of inhaled salbutamol, 
but these are limited by enrolment of recreational subjects. It is now a common opinion 
that inhaled beta2-agonists in therapeutic doses has no advantageous effects in healthy 
athletes. However, animal and human studies, where beta2-agonists are given in systemic 
supra-therapeutic doses daily for few weeks, have shown evidence of improvement of 
muscle strength and endurance performance. Pluim et al. concluded in a systematic 
review and meta-analyses of randomized controlled trials on beta2-agonists and physical 
performance published in 2011 that there is some evidence indicating that systemic beta2-
agonists may have a positive effect on physical performance in healthy subjects(Pluim et 
al 2011). Clenbuterol, another beta2-agonist used in veterinary medicine via prescription 
as a bronchodilator, cardiotonic and tocolytic agent. However used in supratherapeutic 
doses in animals and humans it is misused as a growth promotor with anabolic and 
lipolytic effects.  
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